Parallel import policy raises new possibilities

By Abhai Pandey,Lex Orbis IP Practice
0
531

The pharmaceutical sector dominating the current Indian patent scenario raises several issues to dwell upon. Our previous contribution focusing on the concept of differential pricing, vis-à-vis pharma giant Merck’s anti-diabetes drug Januvia, examined the rationale behind, and the consequent effect of adopting such a practice.

Abhai Pandey, Lawyer, Lex Orbis
Abhai Pandey
Lawyer
Lex Orbis

While patent laws aim at exploiting research and development, alongside attaining commercial success, the extent of leverage granted by law may prove key in determining how “big pharma” balances the act of safeguarding their patents while exploiting potential markets. The concept of “parallel imports” as elucidated in the Patents (Amendment) Act, 2005, is here under the critical eye.

Monopoly rights that a patent confers, allow the patentee to exploit the product to the fullest.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们

Abhai Pandey is a lawyer with LEX ORBIS IP Practice, a law firm specializing in intellectual property issues.

infringement
LexOrbis
709/710 Tolstoy House
15-17 Tolstoy Marg
New Delhi – 110 001
India
Mumbai | Bengaluru
Contact details
Tel: +91 11 2371 6565
Fax: +91 11 2371 6556
Email: mail@lexorbis.com
Website: www.lexorbis.com